Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
Janssen Scientific Affairs, LLC
🇺🇸
United States
Country
🇺🇸
United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News
An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease
Phase 4
Terminated
Conditions
Inflammatory Bowel Diseases
Interventions
Drug: Infliximab
Subscribe
First Posted Date
2015-10-02
Last Posted Date
2020-08-06
Lead Sponsor
Janssen Scientific Affairs, LLC
Target Recruit Count
53
Registration Number
NCT02566889
Subscribe
A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants
Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Rivaroxaban
Drug: Kcentra, a 4-factor PCC
Drug: Saline
Drug: Tranexamic acid
Subscribe
First Posted Date
2015-09-28
Last Posted Date
2017-06-14
Lead Sponsor
Janssen Scientific Affairs, LLC
Target Recruit Count
158
Registration Number
NCT02561923
Subscribe
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
Phase 3
Completed
Conditions
Schizophrenia
Psychotic Disorders
Interventions
Drug: Paliperidone Palmitate Injection (PP1M)
Drug: Aripiprazole
Drug: Paliperidone Palmitate Injection (PP3M)
Drug: Haloperidol
Drug: Olanzapine
Drug: Oral Paliperidone ER
Drug: Perphenazine
Drug: Quetiapine
Drug: Oral Risperidone
Subscribe
First Posted Date
2015-05-01
Last Posted Date
2021-12-03
Lead Sponsor
Janssen Scientific Affairs, LLC
Target Recruit Count
337
Registration Number
NCT02431702
Subscribe
Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants
Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Tramadol HCl
Drug: Moxifloxacin 400 mg
Drug: Tramadol HCl Placebo
Drug: Moxifloxacin Placebo
Subscribe
First Posted Date
2014-12-04
Last Posted Date
2018-08-29
Lead Sponsor
Janssen Scientific Affairs, LLC
Target Recruit Count
68
Registration Number
NCT02307864
Subscribe
An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant
Phase 2
Completed
Conditions
Hepatitits C
Interventions
Drug: Simeprevir
Drug: Sofosbuvir
Drug: Ribavirin
Subscribe
First Posted Date
2014-06-17
Last Posted Date
2016-11-11
Lead Sponsor
Janssen Scientific Affairs, LLC
Target Recruit Count
46
Registration Number
NCT02165189
Subscribe
A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir
Completed
Conditions
Hepatitis C Virus
Interventions
Drug: No intervention
Subscribe
First Posted Date
2014-04-04
Last Posted Date
2016-02-22
Lead Sponsor
Janssen Scientific Affairs, LLC
Target Recruit Count
315
Registration Number
NCT02103699
Subscribe
A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers
Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Tramadol HCl, 50 mg
Drug: Placebo
Subscribe
First Posted Date
2013-09-23
Last Posted Date
2014-12-16
Lead Sponsor
Janssen Scientific Affairs, LLC
Target Recruit Count
30
Registration Number
NCT01947920
Subscribe
Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
Phase 4
Completed
Conditions
Diabetes Mellitus, Type 2
Hypertension
Interventions
Drug: Placebo
Drug: Canagliflozin
Subscribe
First Posted Date
2013-09-11
Last Posted Date
2017-03-03
Lead Sponsor
Janssen Scientific Affairs, LLC
Target Recruit Count
171
Registration Number
NCT01939496
Subscribe
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Phase 3
Completed
Conditions
Percutaneous Coronary Intervention
Atrial Fibrillation
Interventions
Drug: rivaroxaban 15 mg
Drug: rivaroxaban 2.5 mg
Drug: rivaroxaban 10 mg
Drug: vitamin K antagonist (VKA)
Drug: aspirin (ASA)
Drug: clopidogrel
Drug: prasugrel
Drug: ticagrelor
Subscribe
First Posted Date
2013-04-12
Last Posted Date
2017-09-19
Lead Sponsor
Janssen Scientific Affairs, LLC
Target Recruit Count
2124
Registration Number
NCT01830543
Subscribe
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
Phase 4
Completed
Conditions
Hepatosplenic T-Cell Lymphoma
Interventions
Drug: Infliximab
Drug: Golimumab
Subscribe
First Posted Date
2013-03-05
Last Posted Date
2021-03-04
Lead Sponsor
Janssen Scientific Affairs, LLC
Target Recruit Count
1
Registration Number
NCT01804166
Subscribe
Prev
1
2
3
4
5
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy